SCHEDULE 13D/A: Major Shareholder Commits to TriSalus Life Sciences Preferred Stock Exchange and Governance Changes

Frankenius Equity AB, a significant shareholder in TriSalus Life Sciences, Inc., has committed to exchanging its Series A preferred stock for common stock and supporting key corporate governance amendments as part of a new private financing initiative.

Summary

• Frankenius Equity AB and Paul Frankenius, collectively the Reporting Persons, beneficially own 6,732,516 shares of TriSalus Life Sciences, Inc. common stock, representing 20.5% of the class.
• This beneficial ownership includes 6,230,748 shares of common stock, 435,853 shares issuable upon conversion of Series A preferred stock, and 65,915 shares issuable from dividends within 60 days.
• On April 30, 2025, TriSalus Life Sciences entered into a Tender and Support Agreement with certain holders, including Frankenius Equity, as a condition for investors in a private equity financing.
• Under the Support Agreement, Frankenius Equity committed to exchange its Series A preferred stock for common stock in an upcoming Exchange Offer.
• Frankenius Equity also agreed to vote its preferred shares in favor of an amendment to the Certificate of Designations, Preferences and Rights for the Preferred Stock.
• The Exchange Offer will allow preferred stock holders to exchange their shares for common stock at a ratio based on a $10.00 liquidation preference plus accrued dividends (as of August 10, 2027) divided by $4.00.
• The proposed amendment to the Preferred Stock terms includes adding the Issuer's right to call preferred stock for conversion at a price based on a $5.277 current conversion price and eliminating the conversion price reset provision that could lead to a downward adjustment in July 2027.
• Supporting Holders, including Frankenius Equity, collectively hold approximately 55% of the outstanding preferred stock and have agreed to tender their shares and vote for the amendment.
• The Support Agreement is set to terminate upon the earlier of the Issuer's board deciding not to pursue the Exchange Offer or September 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there's potential dilution for common shareholders, the actions simplify the capital structure, remove a potential future dilution risk (conversion price reset), and are a condition for a private financing, which is generally positive for a company's financial stability and growth prospects.

Positives

• The commitment from a major shareholder like Frankenius Equity AB (holding 20.5% of common stock and 55% of preferred stock) signals strong support for the company's strategic direction and private financing.
• The planned exchange offer and conversion of preferred stock to common stock will simplify TriSalus Life Sciences' capital structure, potentially making it more attractive to investors.
• Elimination of the conversion price reset provision for preferred stock removes a potential future dilution risk for existing common shareholders by preventing a downward adjustment in the conversion price in July 2027.

Negatives

• The conversion of preferred stock into common stock will result in dilution for existing common shareholders, as the number of outstanding common shares will increase.
• The elimination of the conversion price reset provision removes a potential benefit for preferred shareholders (who are now converting to common) that could have resulted in more common shares upon conversion if the stock price declined.

Risks

• The Support Agreement may terminate if TriSalus Life Sciences' board of directors decides not to pursue the Exchange Offer, or by September 30, 2025, if the offer is not completed.
• The Exchange Offer requires the filing of a registration statement on Form S-4 with the SEC, which is subject to regulatory review and effectiveness.
• The amendment to the Preferred Stock's Certificate of Designations requires the affirmative vote of holders representing at least a majority of the outstanding preferred stock, although supporting holders already represent approximately 55%.

Future Outlook

TriSalus Life Sciences, Inc. intends to initiate an exchange offer for its Series A preferred stock and hold a special meeting to amend the preferred stock's terms as soon as practicable, aiming to complete these actions by September 30, 2025.

Management Comments

• The Issuer entered into the Tender and Support Agreement as a condition of investors participating in a private financing of its equity securities, indicating a strategic move to facilitate capital raising.
• The Issuer has agreed to take all steps reasonably necessary or desirable to commence the Exchange Offer and hold the Special Meeting as soon as practicable, demonstrating commitment to these corporate actions.

Industry Context

This filing reflects a common strategy in the life sciences sector where companies, particularly those undergoing private financing rounds, seek to simplify their capital structure by converting complex instruments like preferred stock into common equity. This can enhance transparency, reduce administrative burden, and potentially make the company more appealing to a broader investor base by streamlining its equity profile.

Comparison to Industry Standards

• This document details a specific corporate action related to capital structure optimization, rather than operational or financial performance results. Therefore, direct comparisons to industry-standard financial metrics or project outcomes of specific comparable companies are not applicable.
• The process of converting preferred stock to common stock, often in conjunction with new financing, is a standard mechanism used by companies across various industries, including life sciences, to simplify their balance sheets and prepare for future growth or public market activities.

Corporate Governance

Related Party Transactions

• Frankenius Equity AB and Paul Frankenius, as significant beneficial owners (20.5% of common stock) and holders of approximately 55% of the Series A preferred stock, are key parties to the Tender and Support Agreement with TriSalus Life Sciences, Inc.

Stakeholder Impact

• Shareholders (Common): Potential for dilution due to the conversion of preferred stock into common shares, but also benefit from the removal of the preferred stock's conversion price reset provision, which could have caused further dilution.
• Shareholders (Preferred): Will have the opportunity to exchange their preferred shares for common stock, simplifying their holdings, but will lose the potential benefit of a future downward conversion price adjustment.
• Company: Benefits from simplifying its capital structure, facilitating a private financing round, and gaining more control over its outstanding preferred stock through the new call right.

Next Steps

• TriSalus Life Sciences, Inc. is to initiate an exchange offer (the 'Exchange Offer') pursuant to a registration statement on Form S-4 to be filed with the SEC.
• Concurrent with the Exchange Offer, the Issuer will set a special meeting (the 'Special Meeting') to submit an amendment to the Certificate of Designations, Preferences and Rights for the Preferred Stock to a vote of holders.
• The Issuer is committed to taking all steps reasonably necessary or desirable to commence the Exchange Offer and hold the Special Meeting as soon as practicable.

Key Dates

Keywords

TriSalus Life Sciences, SEC filing, Schedule 13D, Frankenius Equity, Paul Frankenius, common stock, preferred stock, exchange offer, tender offer, corporate governance, capital structure, private placement, Series A preferred stock, dilution, conversion price